# Jasper Therapeutics, Inc.: financial statements, quarterly

JSPR · Nasdaq · CIK 1788028 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/jspr.md) · [Financials](/companies/jspr/financials.md) · [Filings](/companies/jspr/filings.md) · [Insiders](/companies/jspr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/jspr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | [8.8](/filings/0001213900-25-107884.md) | [13.2 d](/filings/0001213900-26-036426.md) | [9.8](/filings/0001213900-26-056595.md) | [15.8](/filings/0001213900-26-089592.md) | [9.3](/filings/0001213900-25-107884.md) | [6.8 d](/filings/0001213900-26-036426.md) | [3.6](/filings/0001213900-26-056595.md) | [3.6](/filings/0001213900-26-089592.md) |
| Research and development | $m | [14.8](/filings/0001213900-24-095173.md) | [13.8 d](/filings/0001213900-25-018384.md) | [10.3](/filings/0001213900-25-042011.md) | [11.3](/filings/0001213900-25-075635.md) | [14.5](/filings/0001213900-25-107884.md) | [19.8 d](/filings/0001213900-26-036426.md) | [16.2](/filings/0001213900-26-056595.md) | [21.2](/filings/0001213900-26-089592.md) | [14.4](/filings/0001213900-25-107884.md) | [11.4 d](/filings/0001213900-26-036426.md) | [5.8](/filings/0001213900-26-056595.md) | [5.1](/filings/0001213900-26-089592.md) |
| Operating income | $m | [(19.4)](/filings/0001213900-24-095173.md) | [(17.7) d](/filings/0001213900-25-018384.md) | [(15.1)](/filings/0001213900-25-042011.md) | [(16.0)](/filings/0001213900-25-075635.md) | [(19.9)](/filings/0001213900-25-107884.md) | [(25.3) d](/filings/0001213900-26-036426.md) | [(21.8)](/filings/0001213900-26-056595.md) | [(27.1)](/filings/0001213900-26-089592.md) | [(19.2)](/filings/0001213900-25-107884.md) | [(15.8) d](/filings/0001213900-26-036426.md) | [(11.0)](/filings/0001213900-26-056595.md) | [(9.2)](/filings/0001213900-26-089592.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(17.5)](/filings/0001213900-24-095173.md) | [(16.6) d](/filings/0001213900-25-018384.md) | [(13.7)](/filings/0001213900-25-042011.md) | [(14.6)](/filings/0001213900-25-075635.md) | [(18.6)](/filings/0001213900-25-107884.md) | [(24.3) d](/filings/0001213900-26-036426.md) | [(21.2)](/filings/0001213900-26-056595.md) | [(26.7)](/filings/0001213900-26-089592.md) | [(18.7)](/filings/0001213900-25-107884.md) | [(9.1) d](/filings/0001213900-26-036426.md) | [(1.2)](/filings/0001213900-26-056595.md) | [(2.8)](/filings/0001213900-26-089592.md) |
| Diluted EPS | $ per share | [(1.60)](/filings/0001213900-24-095173.md) | not reported | [(1.03)](/filings/0001213900-25-042011.md) | [(0.97)](/filings/0001213900-25-075635.md) | [(1.24)](/filings/0001213900-25-107884.md) | not reported | [(1.41)](/filings/0001213900-26-056595.md) | [(1.74)](/filings/0001213900-26-089592.md) | [(1.13)](/filings/0001213900-25-107884.md) | not reported | [(0.04)](/filings/0001213900-26-056595.md) | [(0.10)](/filings/0001213900-26-089592.md) |
| Basic EPS | $ per share | [(1.60)](/filings/0001213900-24-095173.md) | not reported | [(1.03)](/filings/0001213900-25-042011.md) | [(0.97)](/filings/0001213900-25-075635.md) | [(1.24)](/filings/0001213900-25-107884.md) | not reported | [(1.41)](/filings/0001213900-26-056595.md) | [(1.74)](/filings/0001213900-26-089592.md) | [(1.13)](/filings/0001213900-25-107884.md) | not reported | [(0.04)](/filings/0001213900-26-056595.md) | [(0.10)](/filings/0001213900-26-089592.md) |

- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [104](/filings/0001213900-23-084970.md) | [86.9](/filings/0001213900-25-018384.md) | [118](/filings/0001213900-24-042805.md) | [107](/filings/0001213900-24-067897.md) | [92.5](/filings/0001213900-24-095173.md) | [71.6](/filings/0001213900-26-036426.md) | [48.8](/filings/0001213900-25-042011.md) | [39.5](/filings/0001213900-25-075635.md) | [50.9](/filings/0001213900-25-107884.md) | [28.7](/filings/0001213900-26-089592.md) | [14.1](/filings/0001213900-26-056595.md) | [7.3](/filings/0001213900-26-089592.md) |
| Current assets | $m | [105](/filings/0001213900-23-084970.md) | [88.9](/filings/0001213900-25-018384.md) | [120](/filings/0001213900-24-042805.md) | [109](/filings/0001213900-24-067897.md) | [94.8](/filings/0001213900-24-095173.md) | [75.8](/filings/0001213900-26-036426.md) | [53.2](/filings/0001213900-25-042011.md) | [43.0](/filings/0001213900-25-075635.md) | [54.6](/filings/0001213900-25-107884.md) | [34.6](/filings/0001213900-26-089592.md) | [20.3](/filings/0001213900-26-056595.md) | [11.6](/filings/0001213900-26-089592.md) |
| Total assets | $m | [110](/filings/0001213900-23-084970.md) | [94.9](/filings/0001213900-25-018384.md) | [126](/filings/0001213900-24-042805.md) | [114](/filings/0001213900-24-067897.md) | [99.4](/filings/0001213900-24-095173.md) | [79.9](/filings/0001213900-26-036426.md) | [57.6](/filings/0001213900-25-042011.md) | [46.5](/filings/0001213900-25-075635.md) | [57.5](/filings/0001213900-25-107884.md) | [35.8](/filings/0001213900-26-089592.md) | [21.2](/filings/0001213900-26-056595.md) | [11.8](/filings/0001213900-26-089592.md) |
| Current liabilities | $m | [11.9](/filings/0001213900-23-084970.md) | [12.4](/filings/0001213900-25-018384.md) | [8.9](/filings/0001213900-24-042805.md) | [10.1](/filings/0001213900-24-067897.md) | [12.5](/filings/0001213900-24-095173.md) | [15.2](/filings/0001213900-26-036426.md) | [12.3](/filings/0001213900-25-042011.md) | [20.5](/filings/0001213900-25-075635.md) | [21.0](/filings/0001213900-25-107884.md) | [13.2](/filings/0001213900-26-089592.md) | [9.0](/filings/0001213900-26-056595.md) | [7.8](/filings/0001213900-26-089592.md) |
| Total liabilities | $m | [16.3](/filings/0001213900-23-084970.md) | [16.5](/filings/0001213900-25-018384.md) | [12.7](/filings/0001213900-24-042805.md) | [13.6](/filings/0001213900-24-067897.md) | [15.7](/filings/0001213900-24-095173.md) | [18.2](/filings/0001213900-26-036426.md) | [15.4](/filings/0001213900-25-042011.md) | [23.0](/filings/0001213900-25-075635.md) | [45.9](/filings/0001213900-25-107884.md) | [31.6](/filings/0001213900-26-089592.md) | [17.8](/filings/0001213900-26-056595.md) | [10.4](/filings/0001213900-26-089592.md) |
| Shareholders' equity | $m | [94.1](/filings/0001213900-24-095173.md) | [78.4](/filings/0001213900-26-036426.md) | [113](/filings/0001213900-25-075635.md) | [100](/filings/0001213900-25-107884.md) | [83.7](/filings/0001213900-25-107884.md) | [61.7](/filings/0001213900-26-089592.md) | [42.2](/filings/0001213900-26-089592.md) | [23.5](/filings/0001213900-26-089592.md) | [11.6](/filings/0001213900-25-107884.md) | [4.2](/filings/0001213900-26-089592.md) | [3.4](/filings/0001213900-26-089592.md) | [1.4](/filings/0001213900-26-089592.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.0) d](/filings/0001213900-24-095173.md) | [(16.5) d](/filings/0001213900-25-018384.md) | [(15.7)](/filings/0001213900-25-042011.md) | [(11.7) d](/filings/0001213900-25-075635.md) | [(14.1) d](/filings/0001213900-25-107884.md) | [(21.1) d](/filings/0001213900-26-036426.md) | [(22.8)](/filings/0001213900-26-056595.md) | [(15.5) d](/filings/0001213900-26-089592.md) | [(17.0) d](/filings/0001213900-25-107884.md) | [(21.9) d](/filings/0001213900-26-036426.md) | [(14.5)](/filings/0001213900-26-056595.md) | [(6.9) d](/filings/0001213900-26-089592.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [36.6](/filings/0001213900-23-084970.md) | [8.8](/filings/0001213900-24-042805.md) | [10.9](/filings/0001213900-24-067897.md) | [11.0](/filings/0001213900-24-095173.md) | [13.3](/filings/0001213900-25-042011.md) | [15.0](/filings/0001213900-25-075635.md) | [15.0](/filings/0001213900-25-107884.md) | [15.0](/filings/0001213900-26-056595.md) | [15.3](/filings/0001213900-26-089592.md) | [16.6](/filings/0001213900-25-107884.md) | [28.7](/filings/0001213900-26-056595.md) | [28.7](/filings/0001213900-26-089592.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 33,274,561 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-089592.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.